A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.
Phase 3
Completed
- Conditions
- Liver Transplant
- Interventions
- Drug: TAC + MMF + corticosteroidsDrug: Minimisation of TAC
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 217
- Registration Number
- NCT02040584
- Locations
- 🇪🇸
Novartis Investigative Site, Zaragoza, Spain
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Phase 2
Completed
- Conditions
- Melanoma and Brain Metastases
- Interventions
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 127
- Registration Number
- NCT02039947
- Locations
- 🇪🇸
Novartis Investigative Site, Zaragoza, Spain
LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 103
- Registration Number
- NCT02040870
- Locations
- 🇨🇳
Novartis Investigative Site, Guangzhou, China
A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
Phase 2
Terminated
- Conditions
- Relapse Remitting Multiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-01-16
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT02038049
- Locations
- 🇺🇦
Novartis Investigative Site, Lviv, Ukraine
Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
Phase 3
Completed
- Conditions
- Polycythemia Vera
- Interventions
- Drug: Best Available Therapy
- First Posted Date
- 2014-01-16
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 149
- Registration Number
- NCT02038036
- Locations
- 🇹🇷
Novartis Investigative Site, Talas / Kayseri, Turkey
A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
Phase 3
Completed
- Conditions
- Choroidal Neovascularization Secondary to Pathologic Myopia
- Interventions
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2019-02-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT02034006
- Locations
- 🇮🇹
Novartis Investigative Site, Napoli, Italy
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 206
- Registration Number
- NCT02034110
- Locations
- 🇸🇪
Novartis Investigative Site, Stockholm, Sweden
Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase
Phase 3
Terminated
- Conditions
- DiabetesMacular EdemaMacular Degeneration
- Interventions
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT02032173
- Locations
- 🇫🇷
Novartis Investigative Site, Poitiers, France
Safety and Efficacy of BAF312 in Dermatomyositis
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT02029274
- Locations
- 🇯🇵
Novartis Investigative Site, Sendai city, Miyagi, Japan
Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT02024932
- Locations
- 🇮🇹
Novartis Investigative Site, Padova, PD, Italy
🇺🇸National Institutes of Health, Bethesda, Maryland, United States